Asia Insurance Review
China-Outbound/U.S.-Inbound M&A
July 2017
With the recent failed attempt by Anbang to obtain the required U.S. regulatory approvals to purchase Fidelity & Guaranty Life, this article provides insight into the U.S. insurance regulatory approval process and how Chinese and other foreign acquirers can navigate them successfully.
This article was first published in the July issue of Asia Insurance Review.
得意分野
Suggested News & Insights
Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private PlacementJuly 17, 2026Sidley Finishes H1 2026 Among Top Three US$1B+ Dealmakers in TexasJuly 16, 2026European Commission Signals Targeted Procedural Simplification of the Foreign Subsidies Regulation – Without Weakening EnforcementJuly 16, 2026Inspection Rights, Internal Affairs, and Personal Jurisdiction: Orchid Global’s Procedural LessonJuly 15, 2026Sidley Advises EMZ Partners on Its Significant Minority Investment in Steinbach & VollmannJuly 13, 2026Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZenecaJuly 13, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
